Tag:

Avastin

Latest Headlines

Latest Headlines

Italy's move to fund unapproved use of Roche's Avastin alarms the industry

In the U.S. pushing drugs for unapproved uses has gotten companies into big trouble. In Italy, the opposite is now true. To save money, the government will pay for patients to be treated for an eye disease with Roche's Avastin, a drug not approved for that use, and has taken legal action against the Swiss drugmaker and marketing partner Novartis for steering physicians toward the pricier Lucentis, which is.

Roche's Avastin and MabThera are added to list of those stolen in Italy

Authorities in Europe have added two Roche cancer drugs to their list of stolen meds that wholesalers and healthcare providers should be on the lookout for. That brings the tally to 5 drugs that the European Medicines Agency says should be closely examined for signs of tampering.

Study: Subbing Avastin for Lucentis could save U.S. $3B on eye treatment

Doctors have long repurposed Roche's Avastin for the eye in place of using the company's pricier Lucentis to save money. Now, a study says the U.S. could save almost $3 billion a year if Medicare patients received the cheaper drug--a prospect Roche isn't so keen on.

Almac at ASCO: Dx spots ovarian cancer patients for whom Roche's Avastin would hurt

Almac Group saved some stellar news for the 2014 ASCO Annual Meeting in Chicago. The U.K. life sciences contract manufacturer said it validated a new diagnostic test that spots a subset of ovarian cancer patients with greater survival odds following standard chemotherapy who should avoid a specific Roche drug. 

Top 10 best-selling cancer drugs of 2013

When it comes to selling big, cancer drugs have a lot going for them. Their targets--deadly diseases that in many cases can kill quickly--put them in high demand, even as they continue to redefine...

EU joins probe into Roche, Novartis eye-drug collusion charges

First it was Italy, then it was France, and now the European Union is stepping up to take a serious look at how Swiss drugmakers Roche and Novartis have handled the marketing of their eye drug Lucentis.

New York men indicted for selling counterfeit and unapproved drugs in U.S.

The FDA more than a year ago warned cancer docs that it had discovered a counterfeit of Roche's Avastin being shipped from a supplier in New York. Now authorities have come down hard on the owners of the company, indicting them on 73 counts for selling more than $17 million worth of fake or unapproved drugs.

French watchdogs raid Novartis, Roche in Lucentis antitrust probe

The French Competition Authority has stepped up its probe of potential Lucentis price-fixing. As The Times of London reports, the antitrust regulators said they raided local offices of Roche and Novartis, looking for evidence of collusion.

The 10 best-selling drugs of 2013

It is the big sellers, the blockbusters--no, megablockbusters--that drug execs aspire to develop. And a look at the top 10 best-selling drugs globally can't help but impress with its big numbers.

Italian prosecutors home in on Roche, Novartis execs in eye-drug collusion probe

Itlaian prosecutors have zeroed in on four executives at Roche and Novartis in their probe of potential fraud in the companies' eye-drug sales, Reuters reports, citing sources. The four executives weren't identified.